330 related articles for article (PubMed ID: 33605827)
21. The safety of pharmacologic options for the treatment of persons with hemophilia.
Franchini M; Mannucci PM
Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
[TBL] [Abstract][Full Text] [Related]
22. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
Lehtinen AE; Baghaei F; Astermark J; Holme PA
Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
[TBL] [Abstract][Full Text] [Related]
23. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
[TBL] [Abstract][Full Text] [Related]
25. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
Brennan Y; Parikh S; McRae S; Tran H
Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
[TBL] [Abstract][Full Text] [Related]
26. Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence.
Ghosh K; Ghosh K
Expert Rev Hematol; 2021 Aug; 14(8):721-730. PubMed ID: 34278926
[TBL] [Abstract][Full Text] [Related]
27. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.
Peyvandi F; Kenet G; Pekrul I; Pruthi RK; Ramge P; Spannagl M
J Thromb Haemost; 2020 Jun; 18(6):1242-1255. PubMed ID: 32115865
[TBL] [Abstract][Full Text] [Related]
28. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Wang C; Young G
Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
[TBL] [Abstract][Full Text] [Related]
29. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
30. The long and short of it: using the new factor products.
Dunn A
Hematology Am Soc Hematol Educ Program; 2015; 2015():26-32. PubMed ID: 26637697
[TBL] [Abstract][Full Text] [Related]
31. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
Sarafanov AG
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239930
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
[TBL] [Abstract][Full Text] [Related]
33. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
Santagostino E
Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
[TBL] [Abstract][Full Text] [Related]
34. Physiological Roles of the von Willebrand Factor-Factor VIII Interaction.
Kiouptsi K; Reinhardt C
Subcell Biochem; 2020; 94():437-464. PubMed ID: 32189311
[TBL] [Abstract][Full Text] [Related]
35. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
36. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD011385. PubMed ID: 31002742
[TBL] [Abstract][Full Text] [Related]
37. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
[TBL] [Abstract][Full Text] [Related]
38. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
[TBL] [Abstract][Full Text] [Related]
39. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
[TBL] [Abstract][Full Text] [Related]
40. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
